Clinical Study of Chinese Herbal Compound Qidan Xiaoke Granules in Patients After Coronary Revascularization
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-80
SponsorLiu Qiang
About this trial
1. Evaluate the efficacy and safety of Qidan Xiaohe granules in patients after coronary revascularization surgery; 2. Develop a traditional Chinese medicine rehabilitation treatment plan and evaluation system for the use of Qidan Xiaohe granules after coronary revascularization surgery; 3. Demonstrate the advantages of traditional Chinese medicine rehabilitation treatment in the postoperative management of coronary revascularization surgery and provide high-level evidence-based medical evidence for the development of traditional Chinese medicine rehabilitation treatment plans.
Eligibility criteria
Qualifiers
Age: 18-80 years old;
no gender limitation;
Meets the diagnostic criteria for coronary heart disease;
Accepts effective PCI procedure;
Disqualifiers
Severe hepatic and/or renal insufficiency
Severe electrolyte disorders
Severe hematological diseases or malignant tumors
Pregnant or breastfeeding women
Trial design
Treatments tested in this trial
- Qidan Xiaoke Granules + Standard Medical Therapy
- Placebo + Standard Medical Therapy
Treatment groups
164 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Liu Qiang
Lead sponsor
The Third Affiliated hospital of Zhejiang Chinese Medical University
Sponsor institution
Source ClinicalTrials.gov